---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-060747"
form_type: "8-K"
ticker: "DWTX"
cik: "0001818844"
company_name: "Dogwood Therapeutics, Inc."
filed_at: "2026-05-14T12:50:28+00:00"
generated_at: "2026-05-14T12:55:23.627435+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Dogwood Q1 net loss $5.0M; Halneuron Phase 2b data due fall 2026

## Summary
- Net loss of $5.0M ($0.15 per share) vs $12.2M ($8.45) in Q1 2025; R&D $2.7M, G&A $2.4M.
- Cash $13.2M provides runway into Q4 2026; closed $12.5M of a $26.9M financing in Jan 2026.
- Halneuron Phase 2b in CINP: 164 enrolled, top-line results expected fall 2026.
- SP16 IND approved; Phase 1b in CIPPN funded by NCI, enrollment starts mid-2026.
- Announced global partnership for legacy antiviral assets with potential value up to $100M to Dogwood and shareholders.

## SEC filing metadata
- accession: 0001104659-26-060747
- form_type: 8-K
- ticker: DWTX
- cik: 0001818844
- company_name: Dogwood Therapeutics, Inc.
- filed_at: 2026-05-14T12:50:28+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818844/000110465926060747/0001104659-26-060747-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818844/000110465926060747/dwtx-20260514x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-060747
- JSON: https://secwatch.observer/filing/0001104659-26-060747.json
- Plain text: https://secwatch.observer/filing/0001104659-26-060747.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.